Mario Balsa, Medical Oncology Resident at Catalan Institute of Oncology, shared a post on X:
“SWOG S2107: encorafenib + cetuximab + nivolumab in MSS BRAF V600E mCRC ASCO26.
- mPFS: 6.4 vs 6.1 months (HR 1.06)
- mOS: 13.5 vs 11.6 months (HR 0.91)
- Biomarker analyses ongoing
Not the destination this study aimed for, but an impressive journey nonetheless!
Turning a biological hypothesis into a completed randomized trial is how the field moves forward.
Congrats to Van Morris and all the team!”
Other articles about ASCO on OncoDaily.
